Role of transplantation in treatment of multiple myeloma in era of novel agents by Małecki, Bartosz et al.
REVIEW ARTICLE
www.journals.viamedica.pl/acta_haematologica_polonica 777
Acta Haematologica Polonica 2021




Copyright © 2021 
The Polish Society of Haematologists and Transfusiologists, 
Insitute of Haematology and Transfusion Medicine. 
All rights reserved.
*Address for correspondence: Bartosz Małecki, Department  
of Hematology and Bone Marrow Transplantation, University of Medical 
Sciences in Poznan, Szamarzewskiego 84, 60–569 Poznan,  
Poland, phone: +48 61 854 93 83, e-mail: bartosz-malecki@wp.pl
Received: 15.10.2020 Accepted: 01.12.2020
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
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Abstract
Multiple myeloma (MM) is a B-cell malignancy characterized by clonal proliferation of plasma cells. Despite the intro-
duction of novel agents such as immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, high- 
-dose chemotherapy with autologous transplantation remains the primary treatment for patients with newly diagnosed 
multiple myeloma.
This review presents the results of clinical trials assessing the effectiveness and safety of various kinds of transplanta-
tion such as single, allogeneic, tandem and salvage. Nowadays, in the era of access to new therapies, the following 
questions should be asked: when is the best time to perform autologous transplantation? What is the significance of 
allogeneic or tandem transplantation? Is the use of a second or third salvage transplant justified? Will chimeric antigen 
receptor T-cell (CAR-T) therapy become a valuable therapeutic method in MM? In this article, we will try to answer these 
questions.
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Introduction
Multiple myeloma (MM) is a monoclonal plasma cell disor-
der characterized by the proliferation of malignant plasma 
cells in the bone marrow, the detection of monoclonal pro-
tein in the serum and/or urine, as well as the occurrence 
of secondary end-organ damage [1]. This disease accounts 
for 1% of all neoplasms overall, and approximately 10% 
of hematological malignancies. The incidence of MM in 
Europe is estimated at 4.5–6.0/100,000, the median 
age at diagnosis is 70, and it is more common in men 
than in women.
The history of treatment for MM has changed since 
the introduction of high-dose chemotherapy with auto-
logous stem cell transplantation (HDT/ASCT), and it has 
been improved by the advent of novel agents such as 
immunomodulatory drugs (IMiDs such as thalidomide, 
lenalidomide and pomalidomide), proteasome inhibitors 
(PIs such as bortezomib, carfilzomib, and ixazomib), and 
most recently monoclonal antibodies such as elotuzumab 
and daratumumab.
In this review, we will try to assess the current role of 
HDT/ASCT based on the results of studies.
ASCT versus non-transplant-based strategies
The first studies to compare the effectiveness of HDT/ASCT 
to standard-dose chemotherapy in multiple myeloma were 
conducted by the Intergroup Francophone du Myèlome 
(IFM) and the Medical Research Council (MRC). In both 
trials, high-dose chemotherapy and ASCT significantly pro-
longed progression-free survival (PFS) and overall survival 
(OS) compared to standard-dose chemotherapy without 
transplantation.
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In a multicenter study, the Medical Research Council’s 
Myeloma VII Trial, 407 patients with previously untreated 
multiple myeloma who were younger than 65 years recei-
ved either conventional-dose combination chemotherapy 
(doxorubicin, carmustine, cyclophosphamide, melphalan) 
or intensive therapy (doxorubicin, vincristine, methylpred-
nisolone, cyclophoshamide) with HDT (melphalan)/ASCT. 
Compared to standard therapy, intensive treatment incre-
ased median survival by almost 12 months: 54.1 months 
versus 42.3 months. The median duration of progression-
-free survival was 31.6 months in the intensive-therapy 
group compared to 19.6 months in the standard-therapy 
group. 206 deaths (89%) were related to myeloma or to-
xicity of treatment. Multiple myeloma was a causal factor 
in more deaths in the standard-therapy group than in the 
intensive-therapy group (62% vs. 49%). Infection was re-
ported in 68 patients (33%), and was more frequent in the 
intensive-therapy group than in the standard-therapy group 
(37% vs. 29%) [2].
The IFM included 200 patients with untreated MM who 
were younger than 65 to receive either conventional-dose 
combination chemotherapy [VMCP (vincristine, melpha-
lan, cyclophosphamide, prednisone), or BVAP (vincristine, 
carmustine, doxorubicin, prednisone)] or intensive therapy 
(both VMCP and BVAP) with HDT(melphalan)/ASCT. The pro-
bability of event-free survival for five years was 28% in the 
high-dose group and 10% in the conventional-dose group 
(p =0.01). The overall estimated rate of five-year survival 
was 52% in the high-dose group and 12% in the conven-
tional-dose group (p =0.03). Treatment-related mortality 
(TRM) was similar in both groups [3].
At the time of these trials (published before 2010), the 
palette of available therapies for MM patients was limited 
and did not include novel agents as part of the initial tre-
atment of patients with newly diagnosed multiple myelo-
ma (NDMM).
A study comparing HDT/ASCT to new therapeutic regi-
mens was conducted by Palumbo et al. [4]. 402 patients 
were enrolled, who after a lenalidomide and dexametha-
sone (Rd) induction were randomized to either two cour-
ses of high-dose melphalan (200 mg/m2) followed by ASCT, 
or six cycles of melphalan, prednisone and lenalidomide 
(MPR). Patients in the ASCT arm had significantly longer 
PFS (median: 43 vs. 22 months; p <0.001) and a higher 
4-year OS rate (82% vs. 65%; p =0.02). Hematologic and 
nonhematologic adverse events were more frequent with 
high-dose melphalan than with MPR, but toxic effects were 
tolerable and did not affect the rate of early death or tre-
atment discontinuation.
The next trial, conducted by Gay et al. [5], included 
389 patients after induction with lenalidomide and de-
xamethasone (Rd). After induction they were randomized 
to consolidation with either RCD regimen (lenalidomide, 
cyclophosphamide, dexamethasone) or two courses of 
high-dose melphalan/ASCT. They also randomized patients 
to maintenance with lenalidomide plus prednisone, or lena-
lidomide alone. PFS during consolidation was significantly 
shorter with chemotherapy plus lenalidomide compared 
to high-dose melphalan and ASCT (median 29 months vs. 
43 months; p <0.0001) and there was a better 4-year OS 
rate (73% vs. 86%; p =0.004). Although HDT/ASCT induced 
more grade III–IV adverse events, no increase in serious 
adverse events or treatment-related deaths were noticed.
The phase III study of the European Myeloma Ne-
twork (EMN02/HO95) included an induction therapy with 
3–4 cycles of VCD (bortezomib, cyclophosphamide and 
dexamethasone) followed by randomization between stan-
dard-dose therapy with VMP (bortezomib, melphalan and 
prednisone) versus high-dose therapy with melphalan at 
200 mg/m2. The primary study endpoint was PFS. Median 
follow-up was 38 months: median PFS was not yet reached 
in the ASCT group and was 44 months in the VMP group; 
3-year estimate of PFS was 64% vs. 57%, respectively 
(p =0.002), which represented a 24% reduced risk of pro-
gression or death in the ASCT group compared to the VMP 
group. 12% of deaths were probably related to treatment: 
68% in the ASCT group and 32% in the VMP group, most 
frequently due to infections (21%), cardiac events (16%), 
and second primary malignancies (53%) [6].
Attal et al. [7] conducted a phase III study to compare 
the efficacy and safety of a combination of lenalidomide, 
bortezomib and dexamethasone (RVD) alone versus RVD 
plus autologous transplantation in patients with newly diag-
nosed myeloma (NDMM). In this trial, PFS was significan-
tly longer in the transplant versus the RVD group (median: 
50 vs. 36 months; p <0.001). Transplantation versus RVD 
alone was associated with increased complete response 
(59% vs. 48%; p =0.006), but OS was similar in both arms 
(4-year survival of 81% in the transplant group vs. 82% in 
the RVD group). Hematologic and nonhematologic adverse 
events (grade III–IV) were more frequent in the transplant 
group versus the RVD group.
More and more single-arm studies are evaluating vario-
us combinations of novel agents as duplets and triplets in 
combination with ASCT. Recently published, the multicenter 
NCT01816971 phase II study has presented the relation-
ship of ASCT with a carfilzomib–lenalidomide–dexametha-
sone (KRd) regimen for patients with NDMM. The patients 
received four cycles of KRd in induction, ASCT, four cycles 
of KRd in consolidation, and 10 cycles of KRd in mainte-
nance. There were high rates of sCR (stringent complete 
remission) and MRD-negative (minimal residual disease) 
at the end of KRd consolidation, and no treatment-related 
deaths were observed [8, 9].
All studies presented in this review comparing ASCT to 
non-transplant therapies in NDMM patients (Table I [2–7]) 
show a superiority of ASCT over the non-transplant appro-
ach in terms of high-quality response and PFS.
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For these reasons, treatment with autologous stem 
cell transplantation should be considered in all patients 
with newly diagnosed multiple myeloma, despite the intro-
duction of novel agents. Eligibility for this procedure should 
be based on performance status (Karnofsky index ≥90) and 
hematopoietic cell transplantation-specific comorbidity in-
dex (HCT-CI) ≤2. It seems that age is not itself a limitation 
for ASCT. The next challenge is to evaluate the necessity 
of HDT/ASCT when a monoclonal antibody such as dara-
tumumab is added to an induction regimen combining an 
IMiD and a PI. To date, there has been no data from on-
going clinical trials comparing a non-transplant approach 
to a transplant approach including daratumumab. Howe-
ver, a few studies have estimated the efficacy and safety 
of this monoclonal antibody in combination with standard 
treatment for transplant-eligible patients (D-VTD vs. VTD 
— the CASSIOPEIA study and D-RVD vs. RVD — the GRIFFIN 
trial). The introduction of daratumumab improved depth 
of response and progression-free survival, with acceptab-
le safety [10, 11].
Single versus tandem ASCT
A tandem transplant is defined as conducting a second 
procedure within 3–6 months of the first. The grounds for 
such a transplant are to achieve a deeper hematological 
response. In the era of new therapies available in the tre-
atment of multiple myeloma, tandem transplantation has 
become less important [12].
In Attal’s trial [13], patients with NDMM were rando-
mized to one or two ASCTs after induction according to 
a VAD regimen (vincristine, doxorubicin, dexamethasone). 
In the group of patients after a single transplant, the the-
rapy included melphalan 140 mg/m2 and TBI (8 Gy). In the 
group of patients who received tandem ASCT, patients re-
ceived the first transplant after preparation of melphalan 
140 mg/m2 alone. Melphalan 140 mg/m2 and TBI (8 Gy) 
were used before the second transplant. The probability 
of 7-year survival after diagnosis in the double transplant 
group compared to the single group was 42% versus 21% 
(p =0.01). CR or VGPR was achieved by 49% of patients 
after a single transplant compared to 63% after tandem 
ASCT (p =0.01), and the probability of relapse-free 7-year 
survival after diagnosis was 13% in the single ASCT group 
and 23% in the tandem ASCT group (p <0.01). In addition, 
the results indicate that double ASCT may be beneficial for 
patients who do not have a VGPR response after undergo-
ing one ASCT. Indeed, the 7-year survival rate among the-
se patients was 11% in the single ASCT group, and 43% in 
the double ASCT group (p <0.001) [14]. Treatment-related 
deaths in the single-transplant group were 4%, and in the 
double-transplant group 6% (p =0.40).
Table I. Comparisons between autologous stem cell transplantation (ASCT) and non-transplant-based strategies (based on [2–7])
Author/year No. Study design Response  (ASCT vs. no ASCT)
PFS  
(ASCT vs. no ASCT)
OS  
(ASCT vs. no ASCT)
Without novel agents
Attal et al., 
1996 [3] 200
VMCP/BVAP ×18 vs. VMCP/ 
/BVAP ×4–6 + (Mel140 + TBI)
ORR: 81% vs. 57%
p <0.001
5-y: 28% vs. 10%
p =0.01
5-y: 52% vs. 12%
p =0.03
Child et al., 
2003 [2] 407
DCCM ×4–12 vs. DVCM ×3   
+ (Mel140 + TBI)
CR 44% vs. 8%
p <0.01
Median 31.6 vs. 19.6 
mo
p <0.001




Palumbo et al., 
2014 [4] 402
Rd ×4 + (MPR ×6 ± R-main) 
vs. (Mel200 ×2 ± R-main) CR 23% vs. 18%
Median 43 vs. 22 mo
p < 0.001
4-y: 82% vs. 65%
p =0.02
Gay et al.,  
2015 [5] 389
Rd ×4 + (CRD ×6 + R or 
RP-main) vs. (Mel200 ×2 + R 
or RP-main)
CR 33–37% vs. 
23–27%
Median 43 vs. 29 mo
p <0.001
4-y: 86% vs. 73%
p =0.004
Cavo et al., 
2017 [6] 1503
VCD ×3–4 + (VMP ±VRD  
+ R-main) vs. (Mel200 ×1 or 
2 ± VRD + R-main)
≥ VGPR: 84% vs. 
75%
p <0.001
3-y: 64% vs. 57%
p =0.002
3-y from randomiza-
tion: 85% in both arms
Attal et al., 
2017 [7] 700
VRD ×3 + (VRD ×5 + R-main) 
vs. (Mel200 + VRD ×2  
+ R-main)
CR: 59% vs. 48%
p =0.03
Median 50 vs. 36 mo
p <0.001
4-y: 81% vs. 82%
p =NS
PFS — progression-free survival; OS — overall survival; VMCP — vincristine–melphalan–cyclophosphamide–prednisone; BVAP — BCNU–vincristine–adriamycin–prednisone; Mel140 — melphalan 140 mg/m2; 
TBI — total body irradiation; ORR — overall response rate; DCCM — doxorubicin–carmustine–cyclophosphamide–melphalan; DVCM — doxorubicin–vincristine–cyclophosphamide–methylprednisolone; 
CR — complete remission; mo — month; Rd — lenalidomide–dexamethasone; MPR — melphalan–prednisone–lenalidomide; R-main — lenalidomide maintenance; Mel200 — melphalan 200 mg/m2; 
CRD — cyclophosphamide–lenalidomide–dexamethasone; R — lenalidomide; RP-main — lenalidomide–prednisone maintenance; VCD — bortezomib–cyclophosphamide–dexamethasone; 
VMP — bortezomib–melphalan–prednisone; VRD — bortezomib–lenalidomide–dexamethasone; VGPR — very good partial response; NS — non-significant
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In another clinical trial conducted by the Dutch-Belgian 
HOVON (Heamato Oncology Cooperative Group) group [15], 
patients were randomized after VAD induction chemother-
apy to receive two cycles of non-myeloablative intermedi-
ate-dose melphalan (70 mg/m2) (single treatment) or the 
same regimen followed by cyclophosphamide 120 mg/kg 
intravenous plus total body irradiation (TBI) 9 Gy and au-
tologous stem cell transplantation (double, intensive treat-
ment). In this study, a significant difference was observed 
for PFS, but not for OS. The number of CRs was higher 
following a tandem procedure. Treatment-related mortal-
ity was 4% in the single treatment group, and 10% in the 
double, intensive arm.
In the EMN02/HO95 phase III clinical trial described 
above [6], the efficacy of a single versus tandem transplant 
was compared at a later stage (415 patients were randomi-
zed). Patients who were eligible to tandem ASCT had a sig-
nificantly higher 3-year PFS rate (74% vs. 62%; p =0.005) 
compared to those who underwent single ASCT.
In the phase III BMT-CTN 0702 STAMINA study, 758 pa-
tients with NDMM were randomized for induction, then 
subjected to firstly ASCT then either a second ASCT or RVD 
consolidation followed by lenalidomide maintenance. In 
contrast to other European studies, the investigators fo-
und no differences in terms of PFS (57% vs. 57%) or OS 
(86% vs. 82%) between the two groups. Tandem ASCT did 
not have an advantage over single ASCT among high-risk 
patients [16].
In the modern era of novel agents, the value of a tan-
dem ASCT is debatable. Tandem ASCT should be conside-
red only for young patients of NDMM with high-risk disease 
characteristics and who did not achieve at least a VGPR 
after the first transplant. A carefully prepared clinical trial 
with modern therapies is needed to answer the questions 
about the role of tandem transplantation.
Importance of salvage ASCT
Salvage ASCT (sASCT) is defined as the administration of 
a second and subsequent ASCT at the time of relapse fol-
lowing a re-induction regimen [12]. According to the recent 
consensus from the American Society of Blood and Mar-
row Transplantation, the European Society for Blood and 
Marrow Transplantation, and the International Myeloma 
Working Group, sASCT should be considered in all patients 
with an initial duration of remission of >18 months following 
upfront ASCT [17]. However, in practice, the role and timing 
of sASCT varies between transplantation centers.
Several studies have evaluated the role of sASCT in 
the relapse of disease. They demonstrated that ASCT for 
a second, or even a third, time is an effective treatment 
option for patients who have previously undergone ASCT.
A prospective evaluation of sASCT was conducted by 
The Myeloma X trial [18]. Patients were randomized to 
sASCT or cyclophosphamide after a bortezomib-based re-
-induction at relapse. This clinical trial showed no OS advan-
tage. The sASCT group had a significant improvement in PFS 
(19 vs. 11 months, p <0.0001) as well as in time to second 
objective disease progression — PFS2 (67 vs. 35 months, 
p <0.0001). After progression, 20 patients (85, 27%) in the 
cyclophosphamide group underwent post-protocol salvage 
ASCT as third or fourth-line treatment. The PFS2 and OS 
in cyclophosphamide group split by subsequent-line sal-
vage ASCT were not significantly different (p =0.269 and 
p =0.139). The authors of this study concluded that pa-
tients derive the greatest benefits from consolidation of sA-
SCT immediately after first reinduction therapy at relapse. 
Delaying salvage ASCT to third-line or later may not confer 
the same degree of advantage.
The next prospective phase III multicenter trial, Re-
LApsE [19], included randomized patients with relapsed 
MM to receive either re-induction with lenalidomide–de-
xamethasone (Rd) followed by salvage ASCT and lenalido-
mide maintenance or Rd continuously. This was the first 
randomized clinical trial to compare salvage ASCT to tre-
atment based on novel agents. This study showed a trend 
towards superior PFS (23.3 vs. 20.1 months; p =0.09) and 
significantly superior OS (NR vs. 57 months; p =0.046) in 
the arm with sASCT.
Garderet et al. [20] assessed retrospectively the outco-
me of salvage third ASCT in patients with relapsed MM. 
They analyzed 570 patients who had a third ASCT be-
tween 1997 and 2010. 482 patients underwent tandem 
ASCT and a third ASCT at first relapse (the AARA group) 
and 88 patients underwent an upfront ASCT with second 
and third transplantations after subsequent relapses (the 
ARARA group). Median follow-up after salvage third ASCT 
was 61 months in AARA and 48 months in ARARA, median 
PFS was 13 and 8 months, and median OS was 33 and 
15 months. According to the relapse-free interval (RFI) 
from the second ASCT, if the RFI was <18 months, then the 
median OS after the third ASCT was 17 months; if the RFI 
was ≥36 months, then the median OS was 64 months in 
the AARA group (p <0.001). In the ARARA group, if the RFI 
was <6 months, median OS after the third ASCT was se-
ven months, 13 months if the RFI was 6–18 months, and 
27 months if the RFI was ≥18 months (p <0.001).
In all the studies presented above, salvage ASCT was 
safe, with an expected increase in hematological and ga-
strointestinal toxicity but without TRM in patients up to 
the age of 75.
These studies have demonstrated that sASCT is a safe 
and effective treatment option for patients with relapsed/ 
/refractory multiple myeloma (RRMM). It is important to 
carefully select patients who might benefit from sASCT. 
It should be used for patients with prolonged remission 
after a first or second ASCT, good general condition, and 
HCT-CI below 3 (low-, intermediate-risk). In the future, 
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the availability of novel agents may improve the respon-
se to a second or even a third ASCT, rather than impai-
ring its usefulness, by enhancing the depth of response 
before ASCT.
Role of allogeneic transplantation  
in treatment of multiple myeloma
Despite increasing the possibilities and effectiveness of 
the treatment of multiple myeloma, it remains an incurab-
le disease with a poor prognosis, especially in high-risk 
patients.
Allogeneic stem cell transplantation (allo-SCT) offers 
a potentially curative option due to a graft-versus-myeloma 
(GvM) effect, and may help achieve long-term PFS. Howe-
ver, currently allo-SCT remains a controversial treatment 
because of considerable toxicity, especially due to immuno-
suppression and severe infections, the risk of graft-versus-
-host disease (GvHD), and a potentially high non-relapse 
mortality (NRM) [21].
Greil et al. [21] conducted analysis of 109 patients 
with multiple myeloma who received allogeneic transplan-
tation with reduced-intensity conditioning (RIC) between 
2000 and 2016. Median patient age was 56 with a 1:1 pro-
portion male:female. Most were treated in terms of indivi-
dual salvage attempts due to relapsed/refractory disease 
after extensive earlier treatment. Only 50% of patients re-
ceived regimens containing PI, and 43% containing IMiDs. 
92% of the cohort received prior auto-SCT, the majority of 
them as a single transplant; 24% received prior auto-SCT 
as a tandem transplant or with a second transplant in the 
case of relapse. After allo-SCT, 50% of the cohort did not 
develop any sign of acute GvHD (aGvHD), in 25% only mild 
symptoms aGvHD grade I were found, and the remaining 
25% were diagnosed with grades II–IV.
At the time of analysis, 42% of the patients were still 
alive: most patients died from PD with accompanying in-
fections. The overall response rate was 70%, the median 
OS was 39.2%, and the median PFS was 14.2 months, 
with a median follow up of 71.5 months. Survival was 
significantly better in patients with response to previous 
therapies compared to patients with progressive disease 
(median OS: 65 vs. 11.5 months, p =0.003; median PFS 
18.4 vs. 5.1 months, p =0.001). Apart from that, survival 
of patients transplanted in first-line was significantly pro-
longed compared to relapsed/refractory disease (median 
OS not reached vs. 21.6 months, p <0.001; median PFS 
47.7 vs. 9.6 months, p <0.001). Treatment-related mor-
tality was comparatively low, with a cumulative incidence 
of 12.4% over 10 years. The authors of this review sug-
gest that the introduction of novel agents in combination 
with allogeneic transplantation in a group of selected pa-
tients with high risk of disease may significantly prolong 
their survival, and could even give the chance of a cure. 
However, these conclusions should await future prospec-
tive clinical trials.
The significance of allogenic transplantation was also 
analyzed in prospective studies comparing tandem ASCT 
versus ASCT-allo-SCT (Table II [22–25]). In all trials, these 
transplantations were a part of the initial therapy.
The IFM99-03/IFM99-04 trials [22] compared myelo-
ma patients with high-risk myeloma (del13 by FISH or an 
elevated beta2-microglobulin). All patients received melp-
halan 200 mg/m2 before single ASCT. The allo-SCT group 
received a reduced but myeloablative regimen of busul-
fan, fludarabine. The no-allo-SCT group received a second 
ASCT after melphalan 220 mg/m2. There were no differen-
ces in response rates (RR), PFS or OS. The 100-day mor-
tality rate in these studies was 4.3%, and the overall TRM 
rate was 10.9%.
Table II. Prospective trials comparing single or double autologous stem cell transplantation (ASCT) with ASCT followed by allogeneic stem 
cell transplantation (allo-SCT) (based on [22–25])
Author/year Treatment No. allo vs. auto Response CR (%) EFS/PFS OS Comments




65 vs. 219 62 vs. 51 Median EFS, 
31.7 vs. 35 
mo
Median OS, 
35 vs. 47.2 
mo
No differences in PFS 
or OS




25 vs. 85 40 vs. 11 Median PFS, 
not reached 
vs. 31 mo
5-y OS, 62% 
vs. 60%






80 vs. 82 55 vs. 26 Median EFS, 
2.8 vs. 2.4 
years
Median OS, 
NR vs. 4.25 
years
Median 7-y follow-up,  
p =0.005 for EFS and  






108 vs. 249 51 vs. 41 22% vs. 12% 49% vs. 
36%
Median 8-y follow-up,  
p =0.027 EFS, p =0.030 
for OS
CR — complete remission; EFS — event-free survival; PFS — progression-free survival; OS — overall survival; RIC — reduced-intensity conditioning; mo — month; TBI — total body irradiation; NR — not reported
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The PETHEMA study [23] included only patients who 
achieved less than a near CR after a single ASCT. 25 pa-
tients with donors proceeded to allo-SCT after a reduced-
-intensity myeloablative regimen of fludarabine, melphalan, 
and they were compared to 85 patients without donors who 
received a second ASCT after a regimen of cyclophospha-
mide, etoposide and carmustine or melphalan 200 mg/m2. 
Statistically significant better CR rates for allo-SCT group 
without differences in PFS or OS and a trend toward a higher 
TRM with allo-RIC (16% vs. 5%; p =0.09) were found.
The next study was conducted by Giaccone et al. [24]. 
All patients received melphalan 200 mg/m2 before single 
ASCT and next allo-SCT after 2 Gy TBI or a second ASCT 
with 100–140 mg melphalan. This trial demonstrated CR 
rates of 55% versus 26%, and improved PFS and OS rates 
(follow-up of 7 years) for the allo-SCT group. Treatment-
-related mortality in the allo-SCT group was 16%, and 2% 
in the ASCT group.
A European trial (EBMT-NMAM2000) [25] compared 
108 patients after a tandem ASCT-allo-SCT treatment 
(fludarabine, 2 Gy TBI) to 249 patients who received 1 or 
2 ASCTs with melphalan 200 mg/m2. This trial also revealed 
a statistically better CR, PFS, and OS rates with follow-up at 
8 years in favor of allo-SCT. Non-relapse mortality was 12% 
versus 2% at 24 months for the auto/allo group (p =0.003).
To sum up the above prospective studies, only two of 
the four trials showed significantly better PFS and OS for 
the allo-SCT group. Therefore, despite biological rationale, 
the role of allo-SCT in the treatment of MM is limited. Ba-
sed on current knowledge, this treatment method should 
be restricted to young, selected and motivated patients 
with high-risk multiple myeloma [26]. Today, as a result of 
various combinations and the wider use of novel agents 
in MM therapy, interest in allo-SCT has decreased signifi-
cantly, and it remains mainly an investigational method.
CAR-T cell therapy: future treatment  
of refractory/recurrent multiple myeloma?
Despite the introduction of many new drugs that have 
dramatically changed the results of MM patients and sig-
nificantly improved overall survival, many patients suffer 
from refractory and recurrent disease even after multiple 
lines of therapy [27, 28].
Table III. B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy trials [27]
Variable NCI University of Pennsylvania JNJ4528 Multicenter Bluebird 2121 Multicenter Nanjing Legend
Authors/pre-
sentation
Ali et al., 
Blood 
2016; Brud-
no et al., 
ASH 2017
Cohen et al., ASH 2016; 
Cohen et al., JCI 2019














Fan et al., ASCO 
2017; Zhao et al.,  
J Hem Onc 2018
n 24 25 29 33 128 57
Vector Retroviral 
vector
Lentiviral vector Lentiviral vector Lentiviral vector Lentiviral vector
Costimulatory 
domain
CD28 4-1BB 4-1BB 4-1BB 4-1BB
Activation do-
main
CD3ζ CD3ζ CD3ζ CD3ζ CD3ζ







Prior lines  
of treatment
9 (median) 7 (median) 5 (median) 8 (median) ≥3 3 (median)
Response 81% ORR; 
>CR 13%
Cohort 1: 6/9 (1 sCR,  
2 VGPR, 2 PR, 1 MR); 
cohort 2: 2/5 (1 PR,  
1 MR); cohort 3: 5/6  
(1 CR, 3 PR, 1 MR)
100% ORR; 76% 








ORR: 88%; 68% 
CR; 5% VGPR; 14% 
PR
PFS — median PFS: 7,2 
mo
Cohort 1: 2.2 mo  
Cohort 2: 1.9 mo  
Cohort 3: 4.2 mo





NCI — National Cancer Institute; ORR — overall response rate; CR — complete remission; sCR — stringent complete remission; VGPR — very good partial response; PR — partial response; MR — minimal respon-
se; PFS — progression-free survival; mo — month
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Treatment options for these patients are particularly 
limited. Advances in cellular immunotherapy will prob-
ably lead to significant improvements in RRMM therapy. 
Chimeric antigen receptor (CAR) T-cell therapy represents 
a major advance in personalized malignance treatment. In 
this, a patient’s own T cells are genetically engineered to 
express a synthetic receptor that binds to a tumor antigen. 
Currently, most clinical trials related to CARs in RRMM are 
directed against B-cell maturation antigen (BCMA). BCMA 
is a member of the tumor necrosis factor superfamily of 
proteins that is primarily expressed by malignant and nor-
mal plasma cells and some mature B cells [29]. The first 
reports have shown promising results and safety profiles 
with even high risk features (Table III) [27]. There are other 
ongoing clinical trials also using CAR-T technology to tar-
get myeloma antigens such as CD138, CS1 glycoprotein 
antigen (SLAMF7), and immunoglobulin light chains. But 
these studies are still at an early stage [30].
Conclusions
Having been introduced approximately 30 years ago, ASCT 
remains the main therapeutic tool in the treatment of 
multiple myeloma for fit patients, despite the introduction 
of novel agents. It is an essential component of a complex 
treatment strategy that connects the use of new therapies 
in induction and consolidation or maintenance with high-
-dose chemotherapy/ASCT, and has an acceptable profile 
of toxic effects [12, 16].
In spite of many attempts to prove the importance of 
tandem and allogenic transplantation, their effectiveness 
has been questioned in many studies. These procedures 
should remain reserved for young, high-risk patients. At 
relapse, salvage ASCT presents an effective treatment 
option. In view of the availability of new drugs, we should 
consider the type and duration of response obtained af-
ter prior ASCT to select those patients who will benefit the 
most from sASCT.
Probably in the near future CAR-T therapy will become 
a significant method of treatment, especially for RRMM. 
However, it remains to be determined when will be the 
best time to incorporate this therapy in MM: as part of in-
duction therapy, in the relapse, as an alternative to ASCT, 
or as an adjunct to ASCT?
To sum up, it is unclear whether CAR-T therapy will pro-
vide another weapon in an increasingly complex arsenal of 
multiple myeloma treatment options, or whether it might 
bring about a new standard of care for a disease that re-
mains incurable.
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